T cell receptor–peptide–major histocompatibility complex (TCR–peptide–MHC complex (also often abbreviated as TCR–pMHC))

The **T cell receptor–peptide–major histocompatibility complex** refers to the molecular complex formed when a T cell receptor (TCR) on the surface of a T lymphocyte recognizes and binds a specific peptide antigen that is presented by a major histocompatibility complex (MHC) protein on an antigen-presenting cell. This interaction is the central step in adaptive immunity, triggering T cell activation and subsequent immune response. The TCR is a heterodimeric cell surface receptor (usually composed of alpha and beta chains), which docks onto the peptide-MHC complex with high specificity. The MHC can be either class I (presents to CD8+ cytotoxic T cells) or class II (presents to CD4+ helper T cells), each with distinct peptide preferences and presentation modes. Structural studies have shown that TCRs engage the MHC and its bound antigen peptide primarily through three highly variable complementarity-determining regions (CDRs), enabling the immune system to recognize an immense diversity of pathogens. This complex is a major therapeutic target in immunotherapy, vaccine development, and treatment of autoimmune, infectious, and oncologic diseases due to its central role in antigen specificity, immune activation, and potential for engineered targeting. Safety concerns focus on avoiding non-specific activation and autoimmune effects.

Other names

TCR–pMHCT cell receptor–peptide–MHCT cell receptor–antigen–MHC complexTCR–MHC–peptide complexT cell receptor–antigen presentation complex

Drugs targeting this complex may block or enhance TCR signaling by disrupting or facilitating recognition of peptide–MHC, alter specificity (engineering), or modulate downstream signaling events (agonism or antagonism during immunotherapy).